Does offering more Advanced Placement courses increase enrollment?

This study utilizes a grant in California that required a group of high schools to increase the number of Advanced Placement (AP) courses offered to their students. The grant provides an arguably exogenous increase in the number of AP courses offered in a school. Using an instrumental variable approach, this analysis shows that offering an additional AP course does not increase total enrollment in AP courses. Instead, students substitute out of other AP subjects to enroll in the new subject being offered. This result suggests that additional AP course access is unlikely to induce students to enroll in more AP courses.Education, Advanced Courses, Education Policy

Does Offering More Advanced Placement Courses Increase Enrollment?

This study utilizes a grant in California that required a group of high schools to increase the number of Advanced Placement(AP) courses offered to their students. The grant provides an arguably exogenous increase in the number of AP coursesoffered in a school. Using an instrumental variable approach, this analysis shows that offering an additional AP course doesnot increase total enrollment in AP courses. Instead, students substitute out of other AP subjects to enroll in the new subject being offered. This result suggests that additional AP course access is unlikely to induce students to enroll in more APcourses

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Car Accidents, Smartphone Adoption and 3G Coverage

This paper examines the relationship between smartphone use by drivers and traffic accidents in California between 2001 and 2013. In order to estimate smartphone use, we first show that widespread adoption of modern smartphones began in 2009 after the release of the iPhone 3G and T-Mobile G1. This information is combined with annual 3G coverage maps that are constructed from cellular tower information in a machine learning framework. In a difference-in-differences framework, we estimate the combined effect of smartphone adoption and 3G coverage along quarter-mile road segments. Controlling for census tract population density, road and year fixed effects, Poisson regression results show that there is a statistically significant increase in the traffic accident rate along a road segment when smartphone use becomes possible. Our preferred specification suggests smartphones caused accident rates to increase by 2.9 percent, resulting in 3500 additional accidents per year in California. Event study results rule out the possibility that our smartphone treatment is capturing a trend in the accident rate. The results are robust to a variety of specifications and consistent with individual-level studies showing that cell phone use leads to lower driving quality. The findings also provide guidance for policies aimed at reducing cell phone related accidents and distracted driving